The peripheral CD138 + population but not the CD138 - population contains myeloma clonogenic cells in plasma cell leukaemia patients

British Journal of Haematology

Volumn 156, Issue 5, 2012, Pages 679-683

  Chiron, David ^a,b,c   Surget, Sylvanie ^a,b,c   Maïga, Sophie ^a,b,c   Bataille, Régis ^a,b,c,d   Moreau, Philippe ^e   Le Gouill, Steven ^a,b,c,e   Amiot, Martine ^a,b,c   Pellat Deceunynck, Catherine ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Equipe labellisée 2008 Ligue Contre le Cancer   (France)

^d Institut de Cancérologie de l'Ouest ^*  (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

CD138; CD20; Clonogenic cells; Myeloma; Plasma cell leukaemia

Indexed keywords

ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD221 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; HLA ANTIGEN CLASS 1; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; SOMATOMEDIN C; STEM CELL FACTOR RECEPTOR; SYNDECAN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; CASE REPORT; CELL CULTURE; CELL POPULATION; CELL SEPARATION; CELL SIZE; CLONOGENESIS; CLONOGENIC ASSAY; COLONY FORMING CELL; COLONY FORMING CELL MM; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LETTER; MYELOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL;

AGED; ANTIGENS, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, PLASMA CELL; MIDDLE AGED; NEOPLASTIC STEM CELLS; SYNDECAN-1; TUMOR STEM CELL ASSAY;

EID: 84857032554     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08904.x     Document Type: Letter

References (10)

1. Billadeau, D., Ahmann, G., Greipp, P. & Van Ness, B. (1993) The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. Journal of Experimental Medicine, 178, 1023-1031.
2. Collette, M., Descamps, G., Pellat-Deceunynck, C., Bataille, R. & Amiot, M. (2007) Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells. European Cytokine Network, 18, 120-126.
3. Hitzler, J.K., Martinez-Valdez, H., Bergsagel, D.B., Minden, M.D. & Messner, H.A. (1991) Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood, 78, 1996-2004.
4. Jakubikova, J., Adamia, S., Kost-Alimova, M., Klippel, S., Cervi, D., Daley, J.F., Cholujova, D., Kong, S.Y., Leiba, M., Blotta, S., Ooi, M., Delmore, J., Laubach, J., Richardson, P.G., Sedlak, J., Anderson, K.C. & Mitsiades, C.S. (2011) Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood, 117, 4409-4419.
5. Jégo, G., Bataille, R. & Pellat-Deceunynck, C. (2001) IL-6 is a growth factor for nonmalignant human plasmablasts. Blood, 97, 1817-1822.
6. Matsui, W., Huff, C.A., Wang, Q., Malehorn, M.T., Barber, J., Tanhehco, Y., Smith, B.D., Civin, C.I. & Jones, R.J. (2004) Characterization of clonogenic multiple myeloma cells. Blood, 103, 2332-2336.
7. Moreaux, J., Klein, B., Bataille, R., Descamps, G., Maïga, S., Hose, D., Goldschmidt, H., Jauch, A., Rème, T., Jourdan, M., Amiot, M. & Pellat-Deceunynck, C. (2011) A high-risk signature for patients with Multiple Myeloma established from the molecular classification of Human Myeloma Cell Lines. Haematologica, 96, 574-582.
8. Paiva, B., Vidriales, M.-B., Cerveró, J., Mateo, G., Pérez, J.J., Montalbán, M.A., Sureda, A., Montejano, L., Gutiérrez, N.C., García de Coca, A., de Las Heras, N., Mateos, M.V., López-Berges, M.C., García-Boyero, R., Galende, J., Hernández, J., Palomera, L., Carrera, D., Martínez, R., de la Rubia, J., Martín, A., Bladé, J., Lahuerta, J.J., Orfao, A. & San Miguel, J.F.; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood, 112, 4017-4023.
9. + memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leukemia and Lymphoma, 45, 1413-1417.
10. Rasmussen, T., Haaber, J., Dahl, I.M., Knudsen, L.M., Kerndrup, G., Lodahl, M., Johnsen, H.E. & Kuehl, M. (2010) Identification of translocation products but not K-RAS mutations in memory B cells from multiple myeloma patients. Haematologica, 95, 1730-1737.